Clinical Trial Update: Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of NXP900 with Osimertinib for advanced EGFR-mutated non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NXP900
• Osimertinib (osimertinib)

Snippet

Sponsor: Nuvectis Pharma, Inc. | Conditions: EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | Phase 1 | Status: RECRUITING